{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:05:07Z","timestamp":1773252307043,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"publisher","award":["QUCG-BRC-23\/24-170"],"award-info":[{"award-number":["QUCG-BRC-23\/24-170"]}],"id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008982","name":"Qatar National Research Fund","doi-asserted-by":"publisher","award":["UREP29-026-3-004"],"award-info":[{"award-number":["UREP29-026-3-004"]}],"id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008982","name":"Qatar National Research Fund","doi-asserted-by":"publisher","award":["UREP28-173-3-057"],"award-info":[{"award-number":["UREP28-173-3-057"]}],"id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007458","name":"Qatar Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004397","name":"Ministry of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["COVID-19-22-43"],"award-info":[{"award-number":["COVID-19-22-43"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.vaccine.2024.06.010","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:41:13Z","timestamp":1717594873000},"page":"126042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting"],"prefix":"10.1016","volume":"42","author":[{"given":"Salma","family":"Younes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadin","family":"Younes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Pieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parveen B.","family":"Nizamuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duaa W.","family":"Al-Sadeq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-2726","authenticated-orcid":false,"given":"Hanin I.","family":"Daas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laith J.","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheyath K.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.06.010_b0005","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard [Internet]. <https:\/\/covid19.who.int\/>."},{"key":"10.1016\/j.vaccine.2024.06.010_b0010","unstructured":"Total COVID-19 vaccine doses administered - Our World in Data. <https:\/\/ourworldindata.org\/grapher\/cumulative-covid-vaccinations?country=\u223cOWID_WRL> [accessed 16 Mar 2023]."},{"key":"10.1016\/j.vaccine.2024.06.010_b0015","unstructured":"Centers for Disease Control and Prevention. Understanding mrna COVID-19 vaccines. Centers for Disease Control and Prevention; 2021. <https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/mrna.html>."},{"issue":"24","key":"10.1016\/j.vaccine.2024.06.010_b0020","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2024.06.010_b0025","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"10309","key":"10.1016\/j.vaccine.2024.06.010_b0030","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2024.06.010_b0035","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMc2119432","article-title":"Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2024.06.010_b0040","doi-asserted-by":"crossref","first-page":"taac130","DOI":"10.1093\/jtm\/taac130","article-title":"Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection","volume":"29","author":"Abou-Saleh","year":"2022","journal-title":"J Travel Med"},{"issue":"4","key":"10.1016\/j.vaccine.2024.06.010_b0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15585\/mmwr.mm7104e3","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2024.06.010_b0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2024.06.010_b0055","article-title":"Humoral response in hemodialysis patients post-SARS-CoV-2 mRNA vaccination: a systematic review of literature","volume":"11","author":"Notarte","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.vaccine.2024.06.010_b0060","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/jmv.27688","article-title":"Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review","volume":"94","author":"Notarte","year":"2022","journal-title":"J Med Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2024.06.010_b0065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/10408363.2022.2038539","article-title":"Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review","volume":"59","author":"Notarte","year":"2022","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2024.06.010_b0070","article-title":"Assessment of the neutralizing antibody response of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in na\u00efve and previously infected individuals: a comparative study","volume":"10","author":"Shurrab","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.vaccine.2024.06.010_b0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10316","key":"10.1016\/j.vaccine.2024.06.010_b0080","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.vaccine.2024.06.010_b0085","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.06.010_b0090","unstructured":"Agency EM. EMA and ECDC recommendations on heterologous vaccination courses against COVID-19: \u2018mix-and-match\u2019 approach can be used for both initial courses and boosters; 2021 <https:\/\/www.ema.europa.eu\/en\/news\/ema-ecdc-recommendations-heterologous-vaccination-courses-against-covid-19-mix-match-approach-can-be>."},{"key":"10.1016\/j.vaccine.2024.06.010_b0095","doi-asserted-by":"crossref","unstructured":"Greinacher A, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384: 2092\u20132101.Return to ref 1 in article.","DOI":"10.1056\/NEJMoa2104840"},{"key":"10.1016\/j.vaccine.2024.06.010_b0100","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"10318","key":"10.1016\/j.vaccine.2024.06.010_b0105","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.06.010_b0110","unstructured":"JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022 (Department of Health and Social Care, 2021)."},{"key":"10.1016\/j.vaccine.2024.06.010_b0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.06.010_b0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/v2020435","article-title":"Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials","volume":"2","author":"Brown","year":"2010","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2024.06.010_b0125","doi-asserted-by":"crossref","first-page":"e0252317","DOI":"10.1371\/journal.pone.0252317","article-title":"Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa","volume":"16","author":"Gededzha","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.06.010_b0130","doi-asserted-by":"crossref","unstructured":"Ismail A, Shurrab FM, Al-Jighefee HT, Al-Sadeq DW, Qotba H, Al-Shaar IA, et al. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays; 2021.","DOI":"10.52586\/4934"},{"issue":"8","key":"10.1016\/j.vaccine.2024.06.010_b0135","article-title":"mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects","volume":"9","author":"Fabricius","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.06.010_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.917905","article-title":"Comparison of IgA, IgG, and neutralizing antibody responses following immunization with Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines","volume":"13","author":"Adjobimey","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.06.010_b0145","article-title":"Covid-19: Antibodies after AstraZeneca and Pfizer vaccines decrease with age and are higher in women, data show","volume":"376","author":"Gareth","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.06.010_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103788","article-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","volume":"75","author":"Azzi","year":"2022","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.06.010_b0155","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2021-221558","article-title":"Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial","volume":"81","author":"Michael","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2024.06.010_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108406","article-title":"Antibody response to COVID-19 vaccine: a point of view that can help to optimize dose distribution","volume":"102","author":"Pieri","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.vaccine.2024.06.010_b0165","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24006698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24006698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:44:31Z","timestamp":1773182671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24006698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0264410X24006698"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126042"}}